Ascendis Pharma A/S (NASDAQ:ASND) Sees Large Drop in Short Interest

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) was the target of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 3,420,000 shares, a drop of 5.5% from the December 31st total of 3,620,000 shares. Based on an average daily volume of 426,500 shares, the short-interest ratio is presently 8.0 days.

Analyst Upgrades and Downgrades

ASND has been the topic of a number of analyst reports. TD Cowen cut their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating on the stock in a research note on Friday, November 15th. UBS Group initiated coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a "buy" rating and a $196.00 price objective on the stock. StockNews.com upgraded Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th. Wedbush reissued an "outperform" rating and set a $181.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Finally, Oppenheimer reduced their price target on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating on the stock in a research note on Friday, November 15th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $191.57.

Ascendis Pharma A/S Stock Up 5.9 %

ASND stock traded up $7.16 during trading on Wednesday, hitting $129.41. 668,286 shares of the company's stock traded hands, compared to its average volume of 443,560. The firm has a market capitalization of $7.85 billion, a P/E ratio of -16.02 and a beta of 0.64. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $161.00. The business has a fifty day simple moving average of $133.13 and a two-hundred day simple moving average of $132.65.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ASND. Wilmington Savings Fund Society FSB bought a new stake in Ascendis Pharma A/S during the third quarter valued at about $30,000. Blue Trust Inc. lifted its position in shares of Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after buying an additional 328 shares during the last quarter. Groupama Asset Managment bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at about $60,000. GAMMA Investing LLC grew its position in shares of Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock worth $80,000 after buying an additional 214 shares during the last quarter. Finally, Signaturefd LLC raised its stake in shares of Ascendis Pharma A/S by 13.2% during the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock worth $102,000 after acquiring an additional 80 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.